From UCLA
Though a much-hoped for vaccination against HIV-AIDs remains elusive and years away, it will, once developed, also require extensive education and promotion to be accepted by those who might benefit most from it because of their high risk of contracting the disease that infects 55,000 Americans annually, say researchers who have just conducted a survey of more than 1,000 Angelenos in STD clinics, needle-exchange programs and in sites offering primary care to Latinos. The survey found that high-risk recipients will get an HIV-AIDS shot if they believe the vaccine is effective, dependent on its side-effects and what it might cost. Given scenarios in which cost and effectiveness varied, those surveyed, on average, gave the potential inoculation an overall acceptance score of 55 out of 100. A disturbing note: 10% of those asked indicated that, depending on how well the vaccine prevented the disease -- and researchers underscore that no immunization is 100% prevention perfect -- they might engage in riskier behaviors.
High-risk folks balk at HIV-AIDS vaccine on efficacy, side-effects, cost
Comments